RADX
Radiopharm Theranostics Limited
NASDAQ · Healthcare · Biotechnology · AU
$2.08
−3.48%Aug 26, 2026, 11:00 UTC
Radiopharm Theranostics dosed the first patient in the second cohort of its Phase 1/2a clinical trial of BetaBart (RV-01), a radiopharmaceutical therapeutic for B7-H3 expressing solid tumors, at a 70 mCi dose, marking the first such therapeutic developed in its joint venture with MD Anderson Cancer Center.
Source:Aug 21, 2026, 06:22 UTC
Radiopharm Theranostics' ADR shares fell 8.4% during mid-day trading on Thursday, trading as low as $2.23 and last at $2.29, with volume down 41% from average.
Source:Jul 24, 2026, 11:15 UTC
Radiopharm Theranostics announces a registered direct offering of 1,281,646 ADSs at US$3.16 per ADS to raise approximately US$4.1 million from U.S. institutional investors.
Jul 22, 2026, 11:05 UTC
Radiopharm Theranostics announced a confirmed durable partial response in its ongoing Phase 1 trial of RAD204 in patients with advanced solid tumors post-immunotherapy.
Source: